E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Paroxysmal Nocturnal Hemoglobinuria |
|
E.1.1.1 | Medical condition in easily understood language |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10055629 |
E.1.2 | Term | Paroxysmal nocturnal hemoglobinuria |
E.1.2 | System Organ Class | 100000004857 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Evaluate the safety and tolerability of 2 dosing regimens of pozelimab and cemdisiran combination therapy during the open-label treatment period (OLTP) |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control, breakthrough hemolysis, and inhibition of total complement hemolysis activity (CH50) • To evaluate the effect of the combination treatment on hemoglobin levels • To evaluate the effect of the combination treatment on red blood cell (RBC) transfusion requirements • To evaluate the effect of the combination treatment on clinical outcome assessments (COAs) measuring fatigue and health related quality of life • To assess the concentrations of total pozelimab in serum and total complement component (C) 5 and cemdisiran in plasma • To assess immunogenicity to pozelimab and cemdisiran • To evaluate the long-term safety and efficacy of pozelimab and cemdisiran in an optional open-label extension period (OLEP) • To assess safety after treatment intensification with pozelimab and cemdisiran |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients with PNH who are receiving treatment with pozelimab monotherapy in the R3918- PNH-1868 study 2. Provide informed consent signed by study patient 3. Willing and able to comply with clinic/remote visits and study-related procedures |
|
E.4 | Principal exclusion criteria |
1. Documented, positive polymerase chain reaction (PCR) or equivalent test based on regional recommendations for COVID-19 or suspected SARS-CoV-2 infection as defined in the protocol 2. Participants with documented history of liver cirrhosis or participants with liver disease with evidence of currently impaired liver function; or participants with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) as described in the protocol 3. Significant protocol deviation(s) in the parent study based on the investigator’s judgment as described in the protocol 4. Any new condition or worsening of an existing condition which, in the opinion of the investigator, would make the participant unsuitable for enrollment or would jeopardize the safety of the participant 5. Known hypersensitivity to cemdisiran or any component of cemdisiran formulation
NOTE: Other protocol-defined Exclusion Criteria apply |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Incidence and severity of treatment-emergent adverse events (TEAEs) (OLTP) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Open-Label Treatment Period (OLTP) 1. Percent change of LDH from pre-treatment to end-of-treatment period 2. Proportion of participants with adequate control of their LDH 3. Proportion of participants with normalization of their LDH 4. Area under the curve (AUC) of LDH over time 5. Proportion of participants with breakthrough hemolysis 6. Proportion of participants with hemoglobin stabilization 7. Change in hemoglobin levels 8. Proportion of participants who are transfusion-free 9. Rate of RBCs transfused 10. Number of units of RBCs transfused 11. Change in CH50 12. Change in fatigue as measured by Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale 13. Mean change in global health status/quality of life scale (GHS/QoL) on the European Organization for Research and Treatment of Cancer: Quality-of-Life Questionnaire core 30 items (EORTC QLQ-C30) 14. Mean change in physical function (PF) scores on the EORTC QLQ-C30 15. Concentrations of total pozelimab in serum 16. Concentrations of cemdisiran in plasma 17. Change from baseline in concentration of total C5 18. Incidence of pozelimab anti-drug antibody (ADA) responses over time 19. Incidence of cemdisiran anti-drug antibody (ADA) responses over time 20. Incidence and severity of TEAEs for participants who received treatment intensification
Optional Open-Label Extension Period (OLEP) 21. Change of LDH 22. Percent change of LDH 23. Proportion of participants with adequate control of their LDH 24. Proportion of participants with normalization of LDH 25. AUC of LDH over time 26. Proportion of participants with breakthrough hemolysis 27. Proportion of participants with hemoglobin stabilization 28. Change in hemoglobin levels 29. Proportion of participants who are transfusion-free 30. Rate of RBCs transfused 31. Number of units of RBCs transfused 32. Change in CH50 33. Percent change in CH50 34. Change in fatigue as measured by FACIT-Fatigue scale 35. Change in GHS/QoL on the EORTC QLQ-C30 36. Change in PF scores on the EORTC QLQ-C30 37. Incidence and severity of TEAEs 38. Concentrations of total pozelimab in serum 39. Concentrations of total C5 40. Concentrations of cemdisiran in plasma 41. Incidence of pozelimab anti-drug antibody (ADA) responses over time 42. Incidence of cemdisiran anti-drug antibody (ADA) responses over time |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
OLTP 1: End of treatment period, approximately 28 weeks 2-4: Day 1 through Week 28, Week 4 through Week 28 5, 6, 17: Baseline through Week 28 7-14: Baseline to Week 28 15, 16, 18, 19: Up to Week 28 20: Through Week 28
OLEP 21, 22, 28, 30, 31: Day 1 to Week 24 and Day 1 to Week 52 32-33: Day 1 to Week 16, Day 1 to Week 24 Day 1 to Week 52 34-36: Day 1 to Week 52 23, 24, 26, 27, 29: Day 1 through Week 24 and Day 1 through Week 52 25: Day 1 through Week 52 37-42: Up to Week 52 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Hong Kong |
Korea, Republic of |
Malaysia |
Taiwan |
Hungary |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the main study is defined as the date of the last visit of the last patient in the OLTP, including patients who discontinued treatment during the OLTP and are being followed in the post-treatment safety follow-up period.
The end of the optional OLEP is defined as the date of the last visit of the last patient in the optional OLEP, including patients who discontinued treatment during the OLEP and are being followed in the post-treatment safety follow-up period. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 5 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |